BioLineRx Ltd.

TASE:BLRX Stock Report

Market Cap: ₪81.1m

BioLineRx Future Growth

Future criteria checks 0/6

BioLineRx's revenue is forecast to decline at 13.4% per annum while its annual earnings are expected to grow at 46.5% per year. EPS is expected to decline by 25.5% per annum.

Key information

46.5%

Earnings growth rate

-25.5%

EPS growth rate

Biotechs earnings growth58.8%
Revenue growth rate-13.4%
Future return on equityn/a
Analyst coverage

Low

Last updated03 Dec 2024

Recent future growth updates

Recent updates

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

Apr 02
Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

Aug 25
BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Apr 05
Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Is BioLineRx (TLV:BLRX) A Risky Investment?

Jun 17
Is BioLineRx (TLV:BLRX) A Risky Investment?

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Feb 26
Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Oct 17
Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Earnings and Revenue Growth Forecasts

TASE:BLRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202710-2-4-11
12/31/20267-10-5-52
12/31/20254-13-9-103
12/31/202425-11-46-313
9/30/202422-20-30-30N/A
6/30/202417-30-30-30N/A
3/31/202412-49-29-29N/A
12/31/20235-61-23-23N/A
9/30/2023N/A-52-34-33N/A
6/30/2023N/A-43-33-32N/A
3/31/2023N/A-32-29-29N/A
12/31/2022N/A-25-27-26N/A
9/30/2022N/A-24-26-26N/A
6/30/2022N/A-22-23-22N/A
3/31/2022N/A-22-23-23N/A
12/31/2021N/A-27-24-24N/A
9/30/2021N/A-35-24-24N/A
6/30/2021N/A-34-24-24N/A
3/31/2021N/A-34-23-23N/A
12/31/2020N/A-30-23-23N/A
9/30/2020N/A-28-23-23N/A
6/30/2020N/A-27-24-24N/A
3/31/2020N/A-26-25-25N/A
12/31/2019N/A-25-23-23N/A
9/30/2019N/A-21-33-22N/A
6/30/2019N/A-24-32-22N/A
3/31/2019N/A-23-32-22N/A
12/31/2018N/A-23-34-24N/A
9/30/2018N/A-25-26-25N/A
6/30/2018N/A-26N/A-26N/A
3/31/2018N/A-26N/A-24N/A
12/31/2017N/A-24N/A-21N/A
9/30/2017N/A-21N/A-18N/A
6/30/2017N/A-18N/A-15N/A
3/31/2017N/A-17N/A-14N/A
12/31/2016N/A-16N/A-15N/A
9/30/2016N/A-15N/A-14N/A
6/30/2016N/A-13N/A-14N/A
3/31/2016N/A-14N/A-15N/A
12/31/2015N/A-14N/A-14N/A
9/30/2015N/A-15N/A-16N/A
6/30/2015N/A-14N/A-15N/A
3/31/2015N/A-13N/A-16N/A
12/31/2014N/A-11N/A-16N/A
9/30/2014N/A-11N/A-15N/A
6/30/2014N/A-16N/A-16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLRX's revenue is expected to decline over the next 3 years (-13.4% per year).

High Growth Revenue: BLRX's revenue is forecast to decline over the next 3 years (-13.4% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BLRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 06:47
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioLineRx Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Michael KingJMP Securities
Justin WalshJonesTrading Institutional Services, LLC